We are interested in hearing your proposals for collaborating with the PCC
The Precision Cancer Consortium (PCC) aims to make precision oncology and comprehensive biomarker testing the new normal. The mission of the PCC is to make biomarker-informed, data-driven patient identification and personalized care standard practice.
If you would like to contribute to this important mission through a collaborative project with the PCC, please read the information below and then complete the collaboration proposal form.
The PCC is dedicated to a future where every person with cancer—regardless of who they are or where they live—can benefit from precision oncology. Through global collaboration, we work to make biomarker-informed, data-driven patient identification and personalized care standard practice.
By collaborating with the PCC, you can:
Shape the future of biomarker testing in a way that you cannot do on your own
Challenges that are ecosystem-related cannot be solved by one stakeholder of the healthcare system alone. The PCC has an impartiality and collective credibility beyond a single pharmaceutical company. This allows the PCC to accomplish more than any individual company.
Demonstrate your commitment to patients and the wider medical community
The PCC is a non-profit organization, and our projects are never product-related or commercially driven. They are chosen on the basis of improving biomarker testing for all patients.
Maximize resource utilization and reach
Collaborate with fellow subject matter experts to share resources and leverage existing materials for new audiences to extend reach.
We are always interested to hear from prospective collaborators who share our vision to make precision oncology and comprehensive biomarker testing the new normal. If you would like to contribute to this important mission, please complete the proposal submission form below.
Through global collaboration, we work to make biomarker-informed, data-driven patient identification and personalized care standard practice by:
- Improving global patient access to precision oncology in both routine care and clinical research
- Educating stakeholders and increasing awareness on how comprehensive biomarker testing and data analysis can improve patient outcomes
- Addressing the challenges of implementing precision oncology, including biomarker testing and data analysis, in healthcare systems to improve equitable treatment and outcomes
The PCC’s core areas of interest include the following:
- Access to comprehensive genomic profiling (CGP) follow-on: policy shaping in Japan
- Liquid biopsy (LBx) follow-on: minimal residual disease (MRD) and monitoring in the USA
- Digital and computational pathology and artificial intelligence (AI)
- Biomarker testing standardization
We are interested in collaborative project proposals that will be conducted in partnership with the PCC. Proposals that do not include a significant element of collaboration with PCC members (e.g., requests for funding only) will not be considered at this time.
The PCC are open to collaborate with healthcare professionals or organisations that share our vision to make precision oncology and comprehensive biomarker testing the new normal.
Please be aware that we do not endorse specific companies, technologies, biomarkers, or therapeutics. Agnostic of these factors, our goal is to foster global collaboration to ensure that precision oncology and biomarker-informed, data-driven, equitable patient identification are integrated into routine care and clinical research.
We are always interested in hearing from prospective collaborators who share our vision of making precision oncology and comprehensive biomarker testing the new normal.
Your proposal will be considered in an initial review conducted on a quarterly basis. We may contact you in the intervening period if we require further information.
Once the initial review is complete, we will inform you of the decision. If your proposal passes initial review, you will be invited to present a more detailed submission. Further details will follow accordingly.
Please submit your proposal here
PCC-252 | January 2026
PCC Members
The PCC is a group of four pharmaceutical companies with a shared vision, coming together to address challenges regarding access, awareness, and research & development of comprehensive genomic testing for cancer patients globally.
The PCC is a non-profit organization.